Multiple Myeloma:@0.747978:0.035749:0.914540:0.035749:0.914540:0.019993:0.747978:0.019993:0.017684:0.011699:0.003848:0.006523:0.003848:0.013123:0.003848:0.012508:0.005330:0.017684:0.010314:0.012508:0.003848:0.012604:0.018049:0.013143
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
91:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
therapy has been shown to significantly re-:@0.084242:0.096166:0.475163:0.096166:0.475163:0.080410:0.084242:0.080410:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.005297:0.011545:0.012950:0.007274:0.005297:0.012931:0.012315:0.012315:0.011545:0.005297:0.007274:0.011545:0.012411:0.015798:0.011545:0.005297:0.006331:0.012411:0.005297:0.007274:0.003656:0.012758:0.011545:0.003656:0.004589:0.004589:0.012257:0.012950:0.011545:0.006331:0.003656:0.010122:0.005296:0.005521:0.012315:0.006388
duce the number of skeletal events (path-:@0.084242:0.112358:0.475152:0.112358:0.475152:0.096602:0.084242:0.096602:0.012989:0.011507:0.012257:0.012315:0.006061:0.006331:0.011545:0.012315:0.006061:0.011545:0.011507:0.017857:0.012931:0.012315:0.005600:0.006061:0.012411:0.005850:0.006061:0.007274:0.009467:0.012315:0.003656:0.012315:0.006331:0.012950:0.003656:0.006061:0.012315:0.010468:0.012315:0.011545:0.006331:0.007274:0.006061:0.006908:0.012931:0.012950:0.006331:0.011545:0.006388
ological fracture, lytic lesions) and improve :@0.084242:0.128551:0.480476:0.128551:0.480476:0.112795:0.084242:0.112795:0.012411:0.003656:0.012411:0.012758:0.003656:0.012257:0.012950:0.003656:0.005157:0.005850:0.005600:0.012950:0.012257:0.006331:0.011507:0.005521:0.012315:0.005138:0.005157:0.003656:0.010122:0.006331:0.003656:0.012257:0.005157:0.003656:0.012315:0.007274:0.003656:0.012411:0.011545:0.007274:0.006908:0.005157:0.012950:0.011545:0.012989:0.005157:0.003656:0.017857:0.012931:0.005521:0.012411:0.010468:0.012506:0.005330
pain control from skeletal-related pain.:@0.084242:0.144743:0.438297:0.144743:0.438297:0.128987:0.084242:0.128987:0.012931:0.012950:0.003656:0.011545:0.005138:0.012257:0.012411:0.011545:0.006331:0.005521:0.012411:0.003656:0.005138:0.005850:0.005521:0.012411:0.017857:0.005138:0.007274:0.009467:0.012315:0.003656:0.012315:0.006331:0.012950:0.003656:0.006196:0.005521:0.012315:0.003656:0.012950:0.006331:0.012315:0.012989:0.005138:0.012931:0.012950:0.003656:0.011545:0.005330
21:@0.438092:0.139116:0.450410:0.139116:0.450410:0.129930:0.438092:0.129930:0.006103:0.006215
n   :@0.084242:0.173995:0.107051:0.173995:0.107051:0.165555:0.084242:0.165555:0.009762:0.003566:0.005914:0.003566
Infection:@0.103485:0.177114:0.185284:0.177114:0.185284:0.161358:0.103485:0.161358:0.004349:0.011738:0.006042:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738
It is recommended that patients with MM re-:@0.084242:0.193306:0.475148:0.193306:0.475148:0.177551:0.084242:0.177551:0.003964:0.006138:0.004118:0.003464:0.007081:0.004118:0.005328:0.012123:0.012065:0.012219:0.017665:0.017665:0.012123:0.011353:0.012796:0.012123:0.012796:0.004118:0.006138:0.011353:0.012758:0.006138:0.004118:0.012738:0.012758:0.006138:0.003464:0.012123:0.011353:0.006138:0.007081:0.004118:0.015606:0.003464:0.006138:0.011353:0.004118:0.017299:0.017299:0.004118:0.005328:0.012123:0.006388
ceive the annual flu vaccine as well as a sin-:@0.084242:0.209499:0.475129:0.209499:0.475129:0.193743:0.084242:0.193743:0.012065:0.012123:0.003464:0.010275:0.012123:0.004276:0.006138:0.011353:0.012123:0.004274:0.012758:0.011353:0.011353:0.011315:0.012758:0.003464:0.004276:0.004474:0.004474:0.011315:0.004276:0.010275:0.012758:0.012065:0.012065:0.003464:0.011353:0.012123:0.004276:0.012758:0.007081:0.004276:0.015606:0.012123:0.003464:0.003464:0.004276:0.012758:0.007081:0.004278:0.012758:0.004276:0.007081:0.003464:0.011353:0.006388
gle pneumococcal vaccine at the time of :@0.084242:0.225691:0.480501:0.225691:0.480501:0.209936:0.084242:0.209936:0.012565:0.003464:0.012123:0.006744:0.012738:0.011353:0.012123:0.011315:0.017665:0.012219:0.012065:0.012219:0.012065:0.012065:0.012758:0.003464:0.006744:0.010275:0.012758:0.012065:0.012065:0.003464:0.011353:0.012123:0.006744:0.012758:0.006138:0.006744:0.006138:0.011353:0.012123:0.006744:0.006138:0.003464:0.017665:0.012123:0.006744:0.012219:0.006042:0.005330
diagnosis, although the evidence for this is :@0.084242:0.241884:0.480522:0.241884:0.480522:0.226128:0.084242:0.226128:0.012796:0.003464:0.012758:0.012565:0.011353:0.012219:0.007081:0.003464:0.007081:0.004945:0.007312:0.012758:0.003464:0.006138:0.011353:0.012219:0.011315:0.012565:0.011353:0.007312:0.006138:0.011353:0.012123:0.007312:0.012123:0.010275:0.003464:0.012796:0.012123:0.011353:0.012065:0.012123:0.007312:0.005657:0.012219:0.005407:0.007312:0.006138:0.011353:0.003464:0.007081:0.007312:0.003464:0.007468:0.005330
weak.  Infection should be treated prompt-:@0.084242:0.258076:0.475201:0.258062:0.475201:0.242306:0.084242:0.242321:0.015606:0.012123:0.012758:0.009275:0.005330:0.011598:0.004445:0.003964:0.011353:0.005657:0.012123:0.012065:0.006138:0.003464:0.012219:0.011353:0.004445:0.007081:0.011353:0.012219:0.011315:0.003464:0.012796:0.004445:0.012738:0.012123:0.004445:0.006138:0.005328:0.012123:0.012758:0.006138:0.012123:0.012796:0.004445:0.012738:0.005328:0.012219:0.017665:0.012738:0.006138:0.633286
22:@0.138946:0.252443:0.151151:0.252443:0.151151:0.243258:0.138946:0.243258:0.005991:0.006215
ly with broad-spectrum antibiotics. Patients :@0.084237:0.274255:0.480496:0.274255:0.480496:0.258499:0.084237:0.258499:0.003464:0.009929:0.007081:0.015606:0.003464:0.006138:0.011353:0.007081:0.012738:0.005326:0.012219:0.012758:0.012796:0.006004:0.007081:0.012738:0.012123:0.012065:0.006138:0.005407:0.011315:0.017665:0.007081:0.012758:0.011353:0.006138:0.003464:0.012738:0.003464:0.012219:0.006138:0.003464:0.012065:0.007081:0.004945:0.007081:0.011007:0.012758:0.006138:0.003464:0.012123:0.011353:0.006138:0.007470:0.005330
with  recurrent,  severe  infections  and  hy-:@0.084237:0.290447:0.475168:0.290447:0.475168:0.274691:0.084237:0.274691:0.015606:0.003464:0.006138:0.011353:0.005330:0.006610:0.005326:0.012123:0.012065:0.011315:0.005407:0.005328:0.012123:0.011353:0.006138:0.004945:0.005330:0.006610:0.007081:0.012123:0.010275:0.012123:0.005328:0.012123:0.005330:0.006610:0.003464:0.011353:0.005657:0.012123:0.012065:0.006138:0.003464:0.012219:0.011353:0.007081:0.005330:0.006610:0.012758:0.011353:0.012796:0.005330:0.006610:0.011353:0.009929:0.006388
pogammaglobulinaemia may benefit from :@0.084237:0.306640:0.480481:0.306640:0.480481:0.290884:0.084237:0.290884:0.012738:0.012219:0.012565:0.012758:0.017665:0.017665:0.012758:0.012565:0.003464:0.012219:0.012738:0.011315:0.003464:0.003464:0.011353:0.012758:0.012123:0.017665:0.003464:0.012758:0.006044:0.017665:0.012758:0.009929:0.006044:0.012738:0.012123:0.011353:0.012123:0.004493:0.004493:0.006138:0.006044:0.005657:0.005328:0.012219:0.018049:0.005330
immunoglobulin replacement with IVIG.:@0.084237:0.322832:0.440547:0.322832:0.440547:0.307076:0.084237:0.307076:0.003464:0.017665:0.017665:0.011315:0.011353:0.012219:0.012565:0.003464:0.012219:0.012738:0.011315:0.003464:0.003464:0.011353:0.004945:0.005328:0.012123:0.012738:0.003464:0.012758:0.012065:0.012123:0.017665:0.012123:0.011353:0.006138:0.004945:0.015606:0.003464:0.006138:0.011353:0.004945:0.003964:0.013123:0.003964:0.016395:0.005330
DISEASE-SPECIFIC TREATMENT  :@0.084242:0.355847:0.425684:0.355847:0.425684:0.336250:0.084242:0.336250:0.016463:0.006585:0.012230:0.012230:0.017404:0.012230:0.012230:0.009878:0.012230:0.013170:0.012230:0.018344:0.006585:0.011289:0.006585:0.018344:0.006585:0.009878:0.013641:0.012230:0.017404:0.009878:0.021167:0.012230:0.017404:0.009878:0.006538:0.006585
FOR MYELOMA:@0.084242:0.374975:0.252164:0.374975:0.252164:0.355378:0.084242:0.355378:0.011289:0.019756:0.013641:0.006585:0.021167:0.014581:0.012230:0.010348:0.019756:0.021167:0.017404
Disease-specific treatment for MM is per-:@0.084242:0.393459:0.475160:0.393459:0.475160:0.377703:0.084242:0.377703:0.014316:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.006388:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.007995:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.007970:0.006042:0.012604:0.005792:0.007974:0.017684:0.017684:0.007978:0.003848:0.007466:0.007986:0.013123:0.012508:0.005792:0.006388
formed  by oncologists and  haematolo-:@0.084242:0.409652:0.475177:0.409652:0.475177:0.393896:0.084242:0.393896:0.006042:0.012604:0.006319:0.018049:0.012508:0.013181:0.005330:0.006185:0.013123:0.010314:0.011526:0.012604:0.011738:0.012450:0.012604:0.003848:0.012604:0.012950:0.003848:0.007466:0.006523:0.007466:0.011526:0.013143:0.011738:0.013181:0.005330:0.006186:0.011738:0.013143:0.012508:0.018049:0.013143:0.006523:0.012604:0.003848:0.012604:0.006388
gists. Patients are evaluated pre-treatment :@0.084242:0.425844:0.480503:0.425844:0.480503:0.410088:0.084242:0.410088:0.012950:0.003848:0.007466:0.006523:0.007466:0.005330:0.003675:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.003662:0.013143:0.005713:0.012508:0.003662:0.012508:0.010660:0.013143:0.003848:0.011699:0.013143:0.006523:0.012508:0.013181:0.003675:0.013123:0.005715:0.012508:0.006388:0.006523:0.005707:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330
for eligibility  for autologous  haematopoi-:@0.084242:0.442037:0.475160:0.442037:0.475160:0.426281:0.084242:0.426281:0.006042:0.012604:0.005792:0.008678:0.012508:0.003848:0.003848:0.012950:0.003848:0.013123:0.003848:0.003848:0.003848:0.006523:0.010314:0.005330:0.003365:0.006042:0.012604:0.005792:0.008678:0.013143:0.011699:0.006523:0.012604:0.003848:0.012604:0.012950:0.012604:0.011699:0.007466:0.005330:0.003339:0.011738:0.013143:0.012508:0.018049:0.013143:0.006523:0.012604:0.013123:0.012604:0.003848:0.006388
etic cell transplantation (HCT), depending :@0.084242:0.458229:0.480484:0.458229:0.480484:0.442473:0.084242:0.442473:0.012508:0.006523:0.003848:0.012450:0.005186:0.012450:0.012508:0.003848:0.003848:0.005195:0.006523:0.005792:0.013143:0.011738:0.007466:0.013123:0.003848:0.013143:0.011738:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.005180:0.007100:0.013143:0.015644:0.008197:0.007100:0.005330:0.005184:0.013181:0.012508:0.013123:0.012508:0.011738:0.013181:0.003848:0.011738:0.012950:0.005330
on the age, comorbidities and functional :@0.084242:0.474713:0.480501:0.474713:0.480501:0.458957:0.084242:0.458957:0.012604:0.011738:0.006870:0.006523:0.011738:0.012508:0.006870:0.013143:0.012950:0.012508:0.005330:0.006870:0.012450:0.012604:0.018049:0.012604:0.005792:0.013123:0.003848:0.013181:0.003848:0.006523:0.003848:0.012508:0.007466:0.006870:0.013143:0.011738:0.013181:0.006870:0.006042:0.011699:0.011738:0.012450:0.006523:0.003848:0.012604:0.011738:0.013143:0.003848:0.005330
testing.  When  compared  with  chemo-:@0.084242:0.491196:0.475152:0.491196:0.475152:0.475440:0.084242:0.475440:0.006523:0.012508:0.007466:0.006523:0.003848:0.011738:0.012950:0.005330:0.005330:0.008909:0.018473:0.011738:0.012508:0.011738:0.005330:0.008907:0.012450:0.012604:0.018049:0.013123:0.013143:0.005711:0.012508:0.013181:0.005330:0.008917:0.015990:0.003848:0.006523:0.011738:0.005330:0.008915:0.012450:0.011738:0.012508:0.018049:0.012596:0.006388
therapy  alone,  intensified  chemotherapy :@0.084242:0.507680:0.480501:0.507680:0.480501:0.491924:0.084242:0.491924:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.003135:0.013143:0.003848:0.012604:0.011738:0.012508:0.005330:0.005330:0.003138:0.003848:0.011738:0.006523:0.012508:0.011738:0.007466:0.003848:0.004686:0.004686:0.012508:0.013181:0.005330:0.003137:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
followed by HCT prolongs both  event-:@0.084242:0.524163:0.475161:0.524163:0.475161:0.508407:0.084242:0.508407:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.012508:0.013181:0.013104:0.013123:0.010314:0.013104:0.013143:0.015644:0.008197:0.013104:0.013123:0.005715:0.012604:0.003848:0.012604:0.011738:0.012950:0.007466:0.013104:0.013123:0.012604:0.006523:0.011738:0.005330:0.007764:0.012508:0.010660:0.012508:0.011738:0.006523:0.006388
free and overall  survival  in patients with :@0.084242:0.540647:0.480470:0.540647:0.480470:0.524891:0.084242:0.524891:0.006042:0.005711:0.012508:0.012508:0.009660:0.013143:0.011738:0.013181:0.009660:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.005330:0.004341:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.004349:0.003848:0.011738:0.009660:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.009660:0.015990:0.003848:0.006523:0.011738:0.005330
MM and remains the standard of care for :@0.084242:0.557130:0.480507:0.557130:0.480507:0.541375:0.084242:0.541375:0.017684:0.017684:0.006186:0.013143:0.011738:0.013181:0.006196:0.005711:0.012508:0.018049:0.013143:0.003848:0.011738:0.007466:0.006196:0.006523:0.011738:0.012508:0.006181:0.007466:0.006523:0.013143:0.011738:0.013181:0.013143:0.005678:0.013181:0.006196:0.012604:0.006042:0.006183:0.012450:0.013143:0.005715:0.012508:0.006185:0.006042:0.012604:0.005792:0.005330
younger patients (less than 70 years) with :@0.084242:0.573614:0.480478:0.573614:0.480478:0.557858:0.084242:0.557858:0.010314:0.012604:0.011699:0.011738:0.012950:0.012508:0.005792:0.006845:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006860:0.007100:0.003848:0.012508:0.007466:0.007466:0.006870:0.006523:0.011738:0.013143:0.011738:0.006852:0.010660:0.010660:0.006860:0.010314:0.012508:0.013143:0.005792:0.007466:0.007100:0.006870:0.015990:0.003848:0.006523:0.011738:0.005330
newly diagnosed MM.:@0.084242:0.590098:0.290617:0.590098:0.290617:0.574342:0.084242:0.574342:0.011738:0.012508:0.015990:0.003848:0.010314:0.005330:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.012508:0.013181:0.005330:0.017684:0.017684:0.005330
22:@0.290609:0.584468:0.303039:0.584468:0.303039:0.575282:0.290609:0.575282:0.006215:0.006215
Transplant-eligible patients are typically :@0.084242:0.606571:0.480461:0.606571:0.480461:0.590815:0.084242:0.590815:0.007620:0.005792:0.013143:0.011738:0.007466:0.013123:0.003848:0.013143:0.011738:0.006523:0.006388:0.012508:0.003848:0.003848:0.012950:0.003848:0.013123:0.003848:0.012508:0.013412:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.013412:0.013143:0.005713:0.012508:0.013412:0.006523:0.010314:0.013123:0.003848:0.012450:0.013143:0.003848:0.003848:0.010314:0.005330
given induction  chemotherapy with a :@0.084242:0.623054:0.480494:0.623054:0.480494:0.607298:0.084242:0.607298:0.012950:0.003848:0.010660:0.012508:0.011738:0.014971:0.003848:0.011738:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.009631:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013125:0.013123:0.010314:0.014971:0.015990:0.003848:0.006523:0.011738:0.014971:0.013143:0.005330
two- or three-drug combination that typi-:@0.084242:0.639538:0.475188:0.639538:0.475188:0.623782:0.084242:0.623782:0.006331:0.015798:0.012411:0.006196:0.008197:0.012411:0.005600:0.008197:0.006331:0.011545:0.005521:0.012315:0.012315:0.006196:0.012989:0.005600:0.011507:0.012758:0.008197:0.012257:0.012411:0.017857:0.012931:0.003656:0.011545:0.012950:0.006331:0.003656:0.012411:0.011545:0.008197:0.006331:0.011545:0.012950:0.006331:0.008197:0.006331:0.010122:0.012931:0.003656:0.006388
cally includes a corticosteroid, an immu-:@0.084242:0.656021:0.475167:0.656021:0.475167:0.640265:0.084242:0.640265:0.012257:0.012950:0.003656:0.003656:0.010122:0.009563:0.003656:0.011545:0.012257:0.003656:0.011507:0.012989:0.012315:0.007274:0.009563:0.012950:0.009563:0.012257:0.012411:0.005600:0.006331:0.003656:0.012257:0.012411:0.007274:0.006331:0.012315:0.005519:0.012411:0.003656:0.012989:0.005138:0.009563:0.012950:0.011545:0.009563:0.003656:0.017857:0.017857:0.011507:0.006388
nomodulatory agent such as lenalidomide :@0.084242:0.672505:0.480499:0.672505:0.480499:0.656749:0.084242:0.656749:0.011545:0.012411:0.017857:0.012411:0.012989:0.011507:0.003656:0.012950:0.006331:0.012411:0.005600:0.010122:0.005561:0.012950:0.012758:0.012315:0.011545:0.006331:0.005561:0.007274:0.011507:0.012257:0.011545:0.005561:0.012950:0.007274:0.005561:0.003656:0.012315:0.011545:0.012950:0.003656:0.003656:0.012989:0.012411:0.017857:0.003656:0.012989:0.012506:0.005330
and/or a proteasome inhibitor such as :@0.084242:0.688988:0.480520:0.688988:0.480520:0.673233:0.084242:0.673233:0.012950:0.011545:0.012989:0.008217:0.012411:0.005600:0.013527:0.012950:0.013527:0.012931:0.005521:0.012411:0.006331:0.012315:0.012950:0.007274:0.012411:0.017857:0.012315:0.013527:0.003656:0.011545:0.011545:0.003656:0.012931:0.003656:0.006331:0.012411:0.005600:0.013527:0.007274:0.011507:0.012257:0.011545:0.013527:0.012950:0.007468:0.005330
bortezomib and/or a chemotherapeutic :@0.084242:0.705472:0.480540:0.705472:0.480540:0.689716:0.084242:0.689716:0.012931:0.012411:0.005600:0.006331:0.012315:0.007986:0.012411:0.017857:0.003656:0.012931:0.011853:0.012950:0.011545:0.012989:0.008217:0.012411:0.005600:0.011853:0.012950:0.011853:0.012257:0.011545:0.012315:0.017857:0.012411:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.012315:0.011507:0.006331:0.003656:0.012450:0.005330
agent such as cyclophosphamide or an :@0.084242:0.721956:0.480497:0.721956:0.480497:0.706200:0.084242:0.706200:0.012950:0.012758:0.012315:0.011545:0.006331:0.010083:0.007274:0.011507:0.012257:0.011545:0.010083:0.012950:0.007274:0.010083:0.012257:0.010122:0.012257:0.003656:0.012411:0.012931:0.011545:0.012411:0.007274:0.012931:0.011545:0.012950:0.017857:0.003656:0.012989:0.012315:0.010083:0.012411:0.005600:0.010083:0.012950:0.011734:0.005330
anthracycline. Patients are typically given :@0.084242:0.738439:0.480455:0.738439:0.480455:0.722683:0.084242:0.722683:0.012950:0.011545:0.006331:0.011545:0.005600:0.012950:0.012257:0.010122:0.012257:0.003656:0.003656:0.011545:0.012315:0.005138:0.007505:0.011199:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007274:0.007505:0.012950:0.005519:0.012315:0.007505:0.006331:0.010122:0.012931:0.003656:0.012257:0.012950:0.003656:0.003656:0.010122:0.007505:0.012758:0.003656:0.010468:0.012315:0.011734:0.005330
four to six cycles of this combination and :@0.084242:0.754923:0.480542:0.754923:0.480542:0.739167:0.084242:0.739167:0.005850:0.012411:0.011507:0.005600:0.008101:0.006331:0.012411:0.008101:0.007274:0.003656:0.009044:0.008101:0.012257:0.010122:0.012257:0.003656:0.012315:0.007274:0.008101:0.012411:0.005850:0.008101:0.006331:0.011545:0.003656:0.007274:0.008101:0.012257:0.012411:0.017857:0.012931:0.003656:0.011545:0.012950:0.006331:0.003656:0.012411:0.011545:0.008101:0.012950:0.011545:0.013183:0.005330
when an adequate response has been :@0.084242:0.771406:0.480515:0.771406:0.480515:0.755650:0.084242:0.755650:0.015798:0.011545:0.012315:0.011545:0.011661:0.012950:0.011545:0.011661:0.012950:0.012989:0.012315:0.012931:0.011507:0.012950:0.006331:0.012315:0.011661:0.005519:0.012315:0.007274:0.012931:0.012411:0.011545:0.007274:0.012315:0.011661:0.011545:0.012950:0.007274:0.011661:0.012931:0.012315:0.012315:0.011736:0.005330
achieved (as determined by the decrease :@0.084242:0.787890:0.480507:0.787890:0.480507:0.772134:0.084242:0.772134:0.012950:0.012257:0.011545:0.003656:0.012315:0.010468:0.012315:0.012989:0.005099:0.006908:0.012950:0.007274:0.005099:0.012989:0.012315:0.006331:0.012315:0.006131:0.017857:0.003656:0.011545:0.012315:0.012989:0.005099:0.012931:0.010122:0.005099:0.006331:0.011545:0.012315:0.005099:0.012989:0.012315:0.012257:0.005521:0.012315:0.012950:0.007274:0.012504:0.005330
in M-protein) are offered an autologous :@0.084242:0.804373:0.480536:0.804373:0.480536:0.788617:0.084242:0.788617:0.003656:0.011545:0.010891:0.017491:0.006196:0.012931:0.005521:0.012411:0.006331:0.012315:0.003656:0.011545:0.006908:0.010891:0.012950:0.005521:0.012315:0.010891:0.012411:0.005905:0.005850:0.012315:0.005521:0.012315:0.012989:0.010891:0.012950:0.011545:0.010891:0.012950:0.011507:0.006331:0.012411:0.003656:0.012411:0.012758:0.012411:0.011507:0.007470:0.005330
transplant. Post-transplant, some specialists :@0.084242:0.820857:0.480465:0.820857:0.480465:0.805101:0.084242:0.805101:0.006331:0.005600:0.012950:0.011545:0.007274:0.012931:0.003656:0.012950:0.011545:0.006331:0.005138:0.005118:0.011199:0.012411:0.007274:0.006331:0.006196:0.006331:0.005600:0.012950:0.011545:0.007274:0.012931:0.003656:0.012950:0.011545:0.006331:0.005138:0.005118:0.007274:0.012411:0.017857:0.012315:0.005118:0.007274:0.012931:0.012315:0.012257:0.003656:0.012950:0.003656:0.003656:0.007274:0.006331:0.007468:0.005330
will treat with maintenance therapy.:@0.084242:0.837340:0.414729:0.837340:0.414729:0.821584:0.084242:0.821584:0.015798:0.003656:0.003656:0.003656:0.005138:0.006331:0.005521:0.012315:0.012950:0.006331:0.005138:0.015798:0.003656:0.006331:0.011545:0.005138:0.017857:0.012950:0.003656:0.011545:0.006331:0.012315:0.011545:0.012950:0.011545:0.012257:0.012315:0.005138:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.005330
Transplant-ineligible patients  are  given :@0.102426:0.853824:0.480478:0.853824:0.480478:0.838068:0.102426:0.838068:0.007620:0.005792:0.013143:0.011738:0.007466:0.013123:0.003848:0.013143:0.011738:0.006523:0.006388:0.003848:0.011738:0.012508:0.003848:0.003848:0.012950:0.003848:0.013123:0.003848:0.012508:0.010737:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.005397:0.013143:0.005715:0.012508:0.005330:0.005394:0.012950:0.003848:0.010660:0.012508:0.011738:0.005330
an initial combination of dexamethasone, :@0.084242:0.870307:0.480482:0.870307:0.480482:0.854551:0.084242:0.854551:0.013143:0.011738:0.005311:0.003848:0.011738:0.003848:0.006523:0.003848:0.013143:0.003848:0.005311:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005311:0.012604:0.006042:0.005311:0.013181:0.012508:0.009236:0.013143:0.018049:0.012508:0.006523:0.011738:0.013143:0.007466:0.012604:0.011738:0.012508:0.005330:0.005330
melphalan and  an  immunomodulatory :@0.084242:0.886791:0.480499:0.886791:0.480499:0.871035:0.084242:0.871035:0.018049:0.012508:0.003848:0.013123:0.011738:0.013143:0.003848:0.013143:0.011738:0.014374:0.013143:0.011738:0.013181:0.005330:0.009034:0.013143:0.011738:0.005330:0.009032:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.018049:0.012604:0.013181:0.011699:0.003848:0.013143:0.006523:0.012604:0.005792:0.010314:0.005330
agent or proteasome inhibitor. Treatment :@0.084242:0.903275:0.480499:0.903275:0.480499:0.887519:0.084242:0.887519:0.013143:0.012950:0.012508:0.011738:0.006523:0.007528:0.012604:0.005792:0.007531:0.013123:0.005715:0.012604:0.006523:0.012498:0.013143:0.007466:0.012604:0.018049:0.012508:0.007543:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.004378:0.005330:0.007533:0.007620:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330
is continued for 12-18 months until the pa-:@0.084242:0.919758:0.475158:0.919758:0.475158:0.904002:0.084242:0.904002:0.003848:0.007466:0.005811:0.012450:0.012604:0.011738:0.006523:0.003848:0.011728:0.011699:0.012508:0.013181:0.005811:0.006042:0.012604:0.005792:0.005802:0.010660:0.010660:0.006388:0.010660:0.010660:0.005823:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005798:0.011699:0.011738:0.006523:0.003848:0.003848:0.005811:0.006523:0.011738:0.012508:0.005800:0.013123:0.013143:0.006388
tient  reaches  a  stable plateau  phase as :@0.084242:0.936242:0.480472:0.936242:0.480472:0.920486:0.084242:0.920486:0.006523:0.003848:0.012508:0.011738:0.006523:0.005330:0.003314:0.005713:0.012508:0.013143:0.012450:0.011738:0.012508:0.007466:0.005330:0.003319:0.013143:0.005330:0.003319:0.007466:0.006523:0.013143:0.013123:0.003848:0.012508:0.008659:0.013123:0.003848:0.013143:0.006523:0.012508:0.013143:0.011699:0.005330:0.003317:0.013123:0.011738:0.013143:0.007466:0.012508:0.008659:0.013143:0.007466:0.005330
determined by  the M-protein; this is  fol-:@0.523643:0.096163:0.914544:0.096163:0.914544:0.080407:0.523643:0.080407:0.013181:0.012508:0.006523:0.012508:0.006317:0.018049:0.003848:0.011738:0.012508:0.013181:0.010179:0.013123:0.010314:0.005330:0.004861:0.006523:0.011738:0.012508:0.010179:0.017684:0.006388:0.013123:0.005715:0.012604:0.006523:0.012508:0.003848:0.011738:0.005330:0.010179:0.006523:0.011738:0.003848:0.007466:0.010179:0.003848:0.007466:0.005330:0.004863:0.006042:0.012604:0.003848:0.006388
lowed  either  by no  therapy  (with  restart-:@0.523643:0.112356:0.914560:0.112356:0.914560:0.096600:0.523643:0.096600:0.003848:0.012604:0.015990:0.012508:0.013181:0.005330:0.002954:0.012508:0.003848:0.006523:0.011738:0.012508:0.005792:0.005330:0.002946:0.013123:0.010314:0.008293:0.011738:0.012604:0.005330:0.002946:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.002950:0.007100:0.015990:0.003848:0.006523:0.011738:0.005330:0.002954:0.005713:0.012508:0.007466:0.006523:0.013143:0.005792:0.006523:0.006388
ing of treatment when the M-protein rises :@0.523643:0.128548:0.919886:0.128548:0.919886:0.112792:0.523643:0.112792:0.003848:0.011738:0.012950:0.006762:0.012604:0.006042:0.006758:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006762:0.015990:0.011738:0.012508:0.011738:0.006756:0.006523:0.011738:0.012508:0.006758:0.017684:0.006388:0.013123:0.005715:0.012604:0.006523:0.012508:0.003848:0.011738:0.006756:0.005792:0.003848:0.007466:0.012508:0.007466:0.005330
significantly) or with single-agent mainte-:@0.523643:0.144741:0.914558:0.144741:0.914558:0.128985:0.523643:0.128985:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.003848:0.010314:0.007100:0.008076:0.012604:0.005792:0.008068:0.015990:0.003848:0.006523:0.011738:0.008068:0.007466:0.003848:0.011738:0.012950:0.003848:0.012508:0.006388:0.013143:0.012950:0.012508:0.011738:0.006523:0.008063:0.018049:0.013143:0.003848:0.011738:0.006523:0.012508:0.006388
nance therapy.:@0.523643:0.160933:0.669019:0.160933:0.669019:0.145177:0.523643:0.145177:0.011738:0.013143:0.011738:0.012450:0.012508:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
Although  myeloma  is presently consid-:@0.541827:0.177126:0.914556:0.177126:0.914556:0.161370:0.541827:0.161370:0.014239:0.003848:0.006523:0.011738:0.012604:0.011699:0.012950:0.011738:0.005330:0.003689:0.018049:0.010314:0.012508:0.003848:0.012604:0.018049:0.013143:0.005330:0.003704:0.003848:0.007466:0.009044:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.006523:0.003848:0.010314:0.009044:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.006388
ered an incurable disease, patients may :@0.523643:0.193318:0.919878:0.193318:0.919878:0.177562:0.523643:0.177562:0.012508:0.005711:0.012508:0.013181:0.008428:0.013143:0.011738:0.008428:0.003848:0.011738:0.012450:0.011699:0.005792:0.013143:0.013123:0.003848:0.012508:0.008428:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.008428:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.008428:0.018049:0.013143:0.010314:0.005330
have a good  quality of  life for  a num-:@0.523643:0.209511:0.914564:0.209511:0.914564:0.193755:0.523643:0.193755:0.011738:0.013143:0.010660:0.012508:0.010699:0.013143:0.010699:0.012950:0.012604:0.012604:0.013181:0.005330:0.005351:0.013123:0.011699:0.013143:0.003848:0.003848:0.006523:0.010314:0.010699:0.012604:0.006042:0.005330:0.005357:0.003848:0.003848:0.006042:0.012508:0.010699:0.006042:0.012604:0.005792:0.005330:0.005351:0.013143:0.010699:0.011738:0.011699:0.018049:0.006388
ber of years with treatment  and conse-:@0.523643:0.225703:0.914573:0.225703:0.914573:0.209947:0.523643:0.209947:0.013123:0.012508:0.005792:0.009852:0.012604:0.006042:0.009852:0.010314:0.012508:0.013143:0.005792:0.007466:0.009852:0.015990:0.003848:0.006523:0.011738:0.009852:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.004510:0.013143:0.011738:0.013181:0.009852:0.012450:0.012604:0.011738:0.007466:0.012508:0.006388
quently,  early diagnosis with appropriate :@0.523643:0.241896:0.919896:0.241896:0.919896:0.226140:0.523643:0.226140:0.013123:0.011699:0.012508:0.011738:0.006523:0.003848:0.010314:0.005330:0.005330:0.002973:0.012508:0.013143:0.005792:0.003848:0.010314:0.008313:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.008313:0.015990:0.003848:0.006523:0.011738:0.008313:0.013143:0.013123:0.013123:0.005719:0.012604:0.013123:0.005792:0.003848:0.013143:0.006523:0.012508:0.005330
treatment of complications and specialist :@0.523643:0.258088:0.919867:0.258088:0.919867:0.242332:0.523643:0.242332:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006254:0.012604:0.006042:0.006258:0.012450:0.012604:0.018049:0.013123:0.003848:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.006273:0.013143:0.011738:0.013181:0.006260:0.007466:0.013123:0.012508:0.012450:0.003848:0.013143:0.003848:0.003848:0.007466:0.006523:0.005330
referral  is of  critical importance.  The  de-:@0.523643:0.274281:0.914564:0.274281:0.914564:0.258525:0.523643:0.258525:0.005713:0.012508:0.006042:0.012508:0.005792:0.005792:0.013143:0.003848:0.005330:0.003677:0.003848:0.007466:0.009025:0.012604:0.006042:0.005330:0.003681:0.012450:0.005792:0.003848:0.006523:0.003848:0.012450:0.013143:0.003848:0.009025:0.003848:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.012450:0.012508:0.005330:0.005330:0.003679:0.008197:0.011738:0.012508:0.005330:0.003677:0.013181:0.012508:0.006388
velopment of new drugs that show an en-:@0.523643:0.290473:0.914558:0.290473:0.914558:0.274717:0.523643:0.274717:0.010660:0.012508:0.003848:0.012604:0.013123:0.018049:0.012508:0.011738:0.006523:0.005449:0.012604:0.006042:0.005448:0.011738:0.012508:0.015990:0.005451:0.013181:0.005792:0.011699:0.012950:0.007466:0.005448:0.006523:0.011738:0.013143:0.006523:0.005448:0.007466:0.011738:0.012604:0.015990:0.005449:0.013143:0.011738:0.005451:0.012508:0.011738:0.006388
hanced ability to induce a remission, with :@0.523643:0.306666:0.919884:0.306666:0.919884:0.290910:0.523643:0.290910:0.011738:0.013143:0.011738:0.012450:0.012508:0.013181:0.006185:0.013143:0.013123:0.003848:0.003848:0.003848:0.006523:0.010314:0.006196:0.006523:0.012604:0.006183:0.003848:0.011738:0.013181:0.011699:0.012450:0.012508:0.006186:0.013143:0.006196:0.005713:0.012508:0.018049:0.003848:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.006196:0.015990:0.003848:0.006523:0.011738:0.005330
lower toxicity, is promising and has led to :@0.523643:0.322858:0.919907:0.322858:0.919907:0.307102:0.523643:0.307102:0.003848:0.012604:0.015990:0.012508:0.005792:0.007102:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.005330:0.007106:0.003848:0.007466:0.007120:0.013123:0.005715:0.012604:0.018049:0.003848:0.007466:0.003848:0.011738:0.012950:0.007110:0.013143:0.011738:0.013181:0.007108:0.011738:0.013143:0.007466:0.007120:0.003848:0.012508:0.013181:0.007120:0.006523:0.012604:0.005330
a significant increase in both progression-:@0.523643:0.339051:0.914546:0.339051:0.914546:0.323295:0.523643:0.323295:0.013143:0.006727:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.006723:0.003848:0.011738:0.012450:0.005711:0.012508:0.013143:0.007466:0.012508:0.006729:0.003848:0.011738:0.006725:0.013123:0.012604:0.006523:0.011738:0.006719:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.006388
free and overall survival, but their use is lim-:@0.523643:0.355243:0.914543:0.355243:0.914543:0.339487:0.523643:0.339487:0.006042:0.005711:0.012508:0.012508:0.004291:0.013143:0.011738:0.013181:0.004291:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.004291:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.004305:0.013123:0.011699:0.006523:0.004291:0.006523:0.011738:0.012508:0.003848:0.005792:0.004291:0.011699:0.007466:0.012508:0.004291:0.003848:0.007466:0.004291:0.003848:0.003848:0.018049:0.006388
ited by prohibitive costs.:@0.523643:0.371436:0.748509:0.371436:0.748509:0.355680:0.523643:0.355680:0.003848:0.006523:0.012508:0.013181:0.005330:0.013123:0.010314:0.005330:0.013123:0.005715:0.012604:0.011738:0.003848:0.013123:0.003848:0.006523:0.003848:0.010660:0.012508:0.005330:0.012450:0.012604:0.007466:0.006523:0.007466:0.005330
REFERENCES:@0.523643:0.400884:0.634479:0.400884:0.634479:0.384850:0.523643:0.384850:0.011161:0.010006:0.009236:0.010006:0.011161:0.010006:0.014239:0.015009:0.010006:0.010006
1. :@0.523636:0.417689:0.542588:0.417689:0.542588:0.403684:0.523636:0.403684:0.009476:0.004738:0.004738
 Schonfeld SJ, Erdmann F, Wiggill T, :@0.559983:0.417689:0.864226:0.417689:0.864226:0.403684:0.559983:0.403684:0.000000:0.008518:0.011067:0.010434:0.011203:0.010434:0.005371:0.011118:0.003421:0.011716:0.009151:0.008518:0.008244:0.004738:0.009151:0.009168:0.005047:0.011716:0.016044:0.011682:0.010434:0.010434:0.009151:0.006205:0.004738:0.009151:0.016521:0.003421:0.011511:0.011511:0.003421:0.003421:0.003421:0.009151:0.005537:0.004738:0.004738
et al:@0.868639:0.417689:0.909810:0.417689:0.909810:0.403684:0.868639:0.403684:0.011118:0.005798:0.009151:0.011682:0.003421
. :@0.909810:0.417689:0.919285:0.417689:0.919285:0.403684:0.909810:0.403684:0.004738:0.004738
Hematologic malignancies in South Africa :@0.559983:0.431823:0.919294:0.431823:0.919294:0.417818:0.559983:0.417818:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.006500:0.016044:0.011682:0.003421:0.003421:0.011511:0.010434:0.011682:0.010434:0.011067:0.003421:0.011118:0.006636:0.006500:0.003421:0.010434:0.006500:0.008518:0.011203:0.010399:0.005798:0.010434:0.006500:0.012657:0.005371:0.005148:0.003421:0.011067:0.011682:0.004738
2000-2006: analysis of data reported to the :@0.559983:0.445958:0.919294:0.445958:0.919294:0.431953:0.559983:0.431953:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738:0.005123:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636:0.005116:0.011203:0.005371:0.005097:0.011716:0.011682:0.005798:0.011682:0.005097:0.005078:0.011118:0.011665:0.011203:0.005148:0.005790:0.011118:0.011716:0.005097:0.005798:0.011203:0.005097:0.005798:0.010434:0.011118:0.004738
National Cancer  Registry. :@0.559983:0.460093:0.789480:0.460093:0.789480:0.446087:0.559983:0.446087:0.012657:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.011597:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.006850:0.010382:0.011118:0.011511:0.003421:0.006636:0.005798:0.005148:0.009168:0.004738:0.004738
Cancer  Med:@0.796314:0.460093:0.909808:0.460093:0.909808:0.446087:0.796314:0.446087:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.006849:0.015719:0.011118:0.011716
. :@0.909808:0.460093:0.919284:0.460093:0.919284:0.446087:0.909808:0.446087:0.004738:0.004738
2016;5(4):728-738. doi:10.1002/cam4.597.:@0.559983:0.474227:0.897264:0.474227:0.897264:0.460222:0.559983:0.460222:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738:0.004738:0.011716:0.011203:0.003421:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.011067:0.011682:0.016044:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738
2. :@0.523636:0.488362:0.542588:0.488362:0.542588:0.474357:0.523636:0.474357:0.009479:0.004734:0.004738
 Kyle RA, Therneau TM, Rajkumar SV, :@0.559981:0.488362:0.840580:0.488362:0.840580:0.474357:0.559981:0.474357:0.000000:0.009767:0.008826:0.003079:0.010776:0.003523:0.010040:0.012315:0.004396:0.003523:0.006944:0.010092:0.010776:0.005162:0.010092:0.010776:0.011340:0.010057:0.003523:0.006944:0.015377:0.004396:0.003523:0.010040:0.011340:0.003130:0.008244:0.010057:0.015702:0.011340:0.004806:0.003523:0.008176:0.009856:0.004396:0.004738
et al:@0.839365:0.488362:0.873882:0.488362:0.873882:0.474357:0.839365:0.474357:0.010776:0.005456:0.003523:0.011340:0.003421
. Inci-:@0.873540:0.488362:0.914556:0.488362:0.914556:0.474357:0.873540:0.474357:0.004396:0.003523:0.003523:0.010092:0.010724:0.003079:0.005679
dence of multiple myeloma in Olmsted Coun-:@0.559983:0.502497:0.914573:0.502497:0.914573:0.488491:0.559983:0.488491:0.011374:0.010776:0.010092:0.010724:0.010776:0.002583:0.010861:0.005029:0.002583:0.015702:0.010057:0.003079:0.005456:0.003079:0.011323:0.003079:0.010776:0.002583:0.015702:0.008826:0.010776:0.003079:0.010861:0.015702:0.011340:0.002583:0.003079:0.010092:0.002583:0.014522:0.003079:0.015702:0.006294:0.005456:0.010776:0.011374:0.002583:0.013564:0.010861:0.010057:0.010092:0.005679
ty, Minnesota. :@0.559983:0.516631:0.683579:0.516631:0.683579:0.502626:0.559983:0.502626:0.005456:0.008826:0.004396:0.012418:0.015377:0.003079:0.010092:0.010092:0.010776:0.006294:0.010861:0.005456:0.011340:0.004396:0.004738
Cancer:@0.691259:0.516631:0.752903:0.516631:0.752903:0.502626:0.691259:0.502626:0.013564:0.011340:0.010092:0.010724:0.010776:0.005148
. 2004;101(11):2667-:@0.752561:0.516631:0.914522:0.516631:0.914522:0.502626:0.752561:0.502626:0.004396:0.012418:0.009134:0.009134:0.009134:0.009134:0.004396:0.009134:0.009134:0.009134:0.005969:0.009134:0.009134:0.005969:0.004396:0.009134:0.009134:0.009134:0.009134:0.005679
2674. doi:10.1002/cncr.20652.:@0.559983:0.530766:0.791242:0.530766:0.791242:0.516761:0.559983:0.516761:0.009134:0.009134:0.009134:0.009134:0.004396:0.004396:0.011374:0.010861:0.003079:0.004396:0.009134:0.009134:0.004396:0.009134:0.009134:0.009134:0.009134:0.007133:0.010724:0.010092:0.010724:0.003549:0.004396:0.009134:0.009134:0.009134:0.009134:0.009134:0.004738
3. :@0.523636:0.544901:0.542588:0.544901:0.542588:0.530895:0.523636:0.530895:0.009476:0.004738:0.004738
  Sant  M,  Allemani  C,  Tereanu  C, :@0.559983:0.544901:0.838108:0.544901:0.838108:0.530895:0.559983:0.530895:0.004738:-0.004738:0.008518:0.011682:0.010434:0.005798:0.004738:0.003409:0.015719:0.004738:0.004738:0.003407:0.012657:0.003421:0.003421:0.011118:0.016044:0.011682:0.010434:0.003421:0.004738:0.003412:0.013906:0.004738:0.004738:0.003409:0.006448:0.011118:0.005075:0.011118:0.011682:0.010434:0.010399:0.004738:0.003412:0.013906:0.004738:0.004738
et  al:@0.841520:0.544901:0.881685:0.544901:0.881685:0.530895:0.841520:0.530895:0.011118:0.005798:0.004738:0.003407:0.011682:0.003421
.  In-:@0.881685:0.544901:0.914547:0.544901:0.914547:0.530895:0.881685:0.530895:0.004738:0.004738:0.003409:0.003866:0.010434:0.005679
cidence of hematologic  malignancies :@0.559983:0.559035:0.919284:0.559035:0.919284:0.545030:0.559983:0.545030:0.011067:0.003421:0.011716:0.011118:0.010434:0.011067:0.011118:0.016762:0.011203:0.005371:0.016762:0.010434:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.004738:0.012014:0.016044:0.011682:0.003421:0.003421:0.011511:0.010434:0.011682:0.010434:0.011067:0.003421:0.011118:0.006636:0.004738
in  Europe  by morphologic  subtype:  re-:@0.559983:0.573170:0.914553:0.573170:0.914553:0.559165:0.559983:0.559165:0.003421:0.010434:0.004738:0.007635:0.009168:0.010399:0.005077:0.011203:0.011665:0.011118:0.004738:0.007634:0.011665:0.009168:0.012384:0.016044:0.011203:0.005148:0.011665:0.010434:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.004738:0.007630:0.006636:0.010399:0.011665:0.005798:0.009168:0.011665:0.011118:0.004738:0.004738:0.007634:0.005078:0.011118:0.005679
sults of the HAEMACARE  project. :@0.559983:0.587010:0.856495:0.587010:0.856495:0.573005:0.559983:0.573005:0.006636:0.010399:0.003421:0.005798:0.006636:0.010707:0.011203:0.005371:0.010707:0.005798:0.010434:0.011118:0.010707:0.011682:0.012657:0.009168:0.015719:0.012657:0.013906:0.012657:0.010382:0.009168:0.004738:0.005961:0.011665:0.005080:0.011203:0.003472:0.011118:0.011067:0.005798:0.004738:0.004738
Blood:@0.862465:0.587010:0.909827:0.587010:0.909827:0.573005:0.862465:0.573005:0.009818:0.003421:0.011203:0.011203:0.011716
. :@0.909827:0.587010:0.919302:0.587010:0.919302:0.573005:0.909827:0.573005:0.004738:0.004738
2010;116(19):3724-3734.  doi:10.1182/blood- :@0.559983:0.600851:0.919279:0.600851:0.919279:0.586846:0.559983:0.586846:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738:0.002981:0.002925:0.011716:0.011203:0.003421:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009489:0.009476:0.007475:0.011665:0.003421:0.011203:0.011203:0.011716:0.005679:0.004738
2010-05-282632.:@0.559983:0.614692:0.689788:0.614692:0.689788:0.600686:0.559983:0.600686:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738
4. :@0.523636:0.628532:0.542588:0.628532:0.542588:0.614527:0.523636:0.614527:0.009476:0.004738:0.004738
  Waxman AJ, Mink PJ, Devesa SS, :@0.559983:0.628532:0.822959:0.628532:0.822959:0.614527:0.559983:0.614527:0.004738:-0.004738:0.015568:0.011682:0.008210:0.016044:0.011682:0.010434:0.002634:0.012657:0.008244:0.004738:0.002634:0.015719:0.003421:0.010434:0.008586:0.002634:0.010126:0.008244:0.004738:0.002634:0.012726:0.011118:0.009476:0.011118:0.006636:0.011682:0.002644:0.008518:0.008518:0.004738:0.004738
et al:@0.820855:0.628532:0.855508:0.628532:0.855508:0.614527:0.820855:0.614527:0.011118:0.005798:0.002634:0.011682:0.003421
. Racial :@0.855508:0.628532:0.919273:0.628532:0.919273:0.614527:0.855508:0.614527:0.004738:0.002634:0.010382:0.011682:0.011067:0.003421:0.011682:0.003421:0.004738
disparities in incidence and outcome in mul-:@0.559983:0.642373:0.914551:0.642373:0.914551:0.628368:0.559983:0.628368:0.011716:0.003421:0.006636:0.011665:0.011682:0.005148:0.003421:0.005798:0.003421:0.011118:0.006636:0.002702:0.003421:0.010434:0.002702:0.003421:0.010434:0.011067:0.003421:0.011716:0.011118:0.010434:0.011067:0.011118:0.002692:0.011682:0.010434:0.011716:0.002702:0.011203:0.010399:0.005798:0.011067:0.011203:0.016032:0.011118:0.002702:0.003421:0.010434:0.002702:0.016044:0.010399:0.003421:0.005679
tiple myeloma: a population-based study. :@0.559983:0.656214:0.919285:0.656214:0.919285:0.642208:0.559983:0.642208:0.005798:0.003421:0.011665:0.003421:0.011118:0.006551:0.016044:0.009168:0.011118:0.003421:0.011203:0.016044:0.011682:0.004738:0.006542:0.011682:0.006551:0.011665:0.011203:0.011665:0.010399:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.005679:0.011665:0.011682:0.006636:0.011118:0.011716:0.006551:0.006636:0.005798:0.010399:0.011716:0.009168:0.004738:0.004738
Blood:@0.559983:0.670054:0.607345:0.670054:0.607345:0.656049:0.559983:0.656049:0.009818:0.003421:0.011203:0.011203:0.011716
. 2010;116(25):5501-5506. doi:10.1182/ :@0.607345:0.670054:0.919277:0.670054:0.919277:0.656049:0.607345:0.656049:0.004738:0.004319:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009496:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738:0.004350:0.011716:0.011203:0.003421:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007492:0.004738
blood-2010-07-298760.:@0.559983:0.683895:0.744676:0.683895:0.744676:0.669890:0.559983:0.669890:0.011665:0.003421:0.011203:0.011203:0.011716:0.005679:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738
5. :@0.523636:0.697594:0.542588:0.697594:0.542588:0.683589:0.523636:0.683589:0.009476:0.004738:0.004738
  Kyle RA, Gertz MA, Witzig TE, :@0.559983:0.697594:0.804053:0.697594:0.804053:0.683589:0.559983:0.683589:0.004738:-0.004738:0.010109:0.009168:0.003421:0.011118:0.006260:0.010382:0.012657:0.004738:0.006243:0.014915:0.011118:0.005148:0.005798:0.007269:0.006247:0.015719:0.012657:0.004738:0.006243:0.016519:0.003421:0.005798:0.007269:0.003421:0.011511:0.006252:0.007286:0.009168:0.004738:0.004738
et al:@0.805550:0.697594:0.843818:0.697594:0.843818:0.683589:0.805550:0.683589:0.011118:0.005798:0.006248:0.011682:0.003421
. Review :@0.843818:0.697594:0.919272:0.697594:0.919272:0.683589:0.843818:0.683589:0.004738:0.006250:0.010382:0.011118:0.009476:0.003421:0.011118:0.014214:0.004738
of 1027 Patients with Newly Diagnosed Mul-:@0.559983:0.711435:0.914537:0.711435:0.914537:0.697430:0.559983:0.697430:0.011203:0.005371:0.004156:0.009476:0.009476:0.009476:0.009476:0.004172:0.010126:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004156:0.014214:0.003421:0.005798:0.010434:0.004156:0.012657:0.011118:0.014214:0.003421:0.009168:0.004156:0.012726:0.003421:0.011682:0.011511:0.010434:0.011203:0.006636:0.011118:0.011716:0.004156:0.015719:0.010399:0.003421:0.005679
tiple Myeloma. :@0.559983:0.725276:0.693876:0.725276:0.693876:0.711271:0.559983:0.711271:0.005798:0.003421:0.011665:0.003421:0.011118:0.010639:0.015719:0.009168:0.011118:0.003421:0.011203:0.016044:0.011682:0.004738:0.004738
Mayo Clin Proc:@0.699777:0.725276:0.837552:0.725276:0.837552:0.711271:0.699777:0.711271:0.015719:0.011682:0.009168:0.011203:0.010639:0.013906:0.003421:0.003421:0.010434:0.010639:0.010126:0.005148:0.011203:0.011067
. 2003;78 :@0.837552:0.725276:0.919260:0.725276:0.919260:0.711271:0.837552:0.711271:0.004738:0.010639:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738
(1):21-33. doi:10.4065/78.1.21.:@0.559983:0.739116:0.801616:0.739116:0.801616:0.725111:0.559983:0.725111:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738:0.004738:0.011716:0.011203:0.003421:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.009476:0.009476:0.004738:0.009476:0.004738:0.009476:0.009476:0.004738
6. :@0.523636:0.752957:0.542588:0.752957:0.542588:0.738952:0.523636:0.738952:0.009476:0.004738:0.004738
  Groot JJB de, Webb MJ, Raubenheimer JE, :@0.559983:0.752957:0.919291:0.752957:0.919291:0.738952:0.559983:0.738952:0.004738:-0.004738:0.014915:0.005078:0.011203:0.011203:0.005798:0.004762:0.008244:0.008244:0.009818:0.004772:0.011716:0.011118:0.004738:0.004772:0.015618:0.011118:0.011665:0.011665:0.004772:0.015719:0.008244:0.004738:0.004772:0.010382:0.011682:0.010399:0.011665:0.011118:0.010434:0.010434:0.011118:0.003421:0.016044:0.011118:0.005148:0.004762:0.008244:0.009168:0.004738:0.004738
et  al:@0.559983:0.766798:0.599465:0.766798:0.599465:0.752792:0.559983:0.752792:0.011118:0.005798:0.004738:0.002725:0.011682:0.003421
.  Concomitant  HIV infection  in newly :@0.599465:0.766798:0.919289:0.766798:0.919289:0.752792:0.599465:0.752792:0.004738:0.004738:0.002725:0.013906:0.011203:0.010434:0.011067:0.011193:0.016044:0.003421:0.005798:0.011682:0.010434:0.005798:0.004738:0.002723:0.011682:0.003866:0.012007:0.007475:0.003421:0.010434:0.005371:0.011118:0.011067:0.005798:0.003421:0.011203:0.010434:0.004738:0.002728:0.003421:0.010434:0.007475:0.010434:0.011118:0.014214:0.003421:0.009168:0.004738
diagnosed multiple myeloma patients is :@0.559983:0.780638:0.919277:0.780638:0.919277:0.766633:0.559983:0.766633:0.011716:0.003421:0.011682:0.011511:0.010434:0.011203:0.006636:0.011118:0.011716:0.011135:0.016044:0.010399:0.003421:0.005798:0.003421:0.011665:0.003421:0.011118:0.011135:0.016044:0.009168:0.011118:0.003421:0.011203:0.016044:0.011682:0.011135:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.011135:0.003421:0.006636:0.004738
hard to recognise and should be tested :@0.559983:0.794479:0.919291:0.794479:0.919291:0.780474:0.559983:0.780474:0.010434:0.011682:0.005044:0.011716:0.009082:0.005798:0.011203:0.009082:0.005078:0.011118:0.011067:0.011203:0.011511:0.010434:0.003421:0.006636:0.011118:0.009082:0.011682:0.010434:0.011716:0.009082:0.006636:0.010434:0.011203:0.010399:0.003421:0.011716:0.009082:0.011665:0.011118:0.009082:0.005798:0.011118:0.006636:0.005798:0.011118:0.011716:0.004738
for routinely in areas of high endemicity. :@0.559983:0.808614:0.919291:0.808614:0.919291:0.794608:0.559983:0.794608:0.005371:0.011203:0.005148:0.008723:0.005078:0.011203:0.010399:0.005798:0.003421:0.010434:0.011118:0.003421:0.009168:0.008723:0.003421:0.010434:0.008723:0.011682:0.005078:0.011118:0.011682:0.006636:0.008723:0.011203:0.005371:0.008723:0.010434:0.003421:0.011511:0.010434:0.008723:0.011118:0.010434:0.011716:0.011118:0.016044:0.003421:0.011067:0.003421:0.005798:0.009168:0.004738:0.004738
South African Med J:@0.559983:0.822748:0.736671:0.822748:0.736671:0.808743:0.559983:0.808743:0.008518:0.011203:0.010399:0.005798:0.010434:0.007919:0.012657:0.005371:0.005148:0.003421:0.011067:0.011682:0.010434:0.007919:0.015719:0.011118:0.011716:0.007919:0.008244
. 2017;107(9):781-787. :@0.736671:0.822748:0.919270:0.822748:0.919270:0.808743:0.736671:0.808743:0.004738:0.007919:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009503:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738:0.004738
doi:10.7196/SAMJ.2017.v107i9.12360.:@0.559983:0.836883:0.860301:0.836883:0.860301:0.822878:0.559983:0.822878:0.011716:0.011203:0.003421:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.008518:0.012657:0.015719:0.008244:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.003421:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738
7. :@0.523636:0.851018:0.542588:0.851018:0.542588:0.837012:0.523636:0.837012:0.009476:0.004738:0.004738
  Dal Maso  L,  Franceschi  S.  Epidemiology :@0.559983:0.851018:0.919279:0.851018:0.919279:0.837012:0.559983:0.837012:0.004738:-0.004738:0.012726:0.011682:0.003421:0.010656:0.015719:0.011682:0.006636:0.011203:0.004738:0.005908:0.007902:0.004738:0.004738:0.005904:0.008296:0.005148:0.011682:0.010434:0.011067:0.011118:0.006636:0.011067:0.010434:0.003421:0.004738:0.005904:0.008518:0.004738:0.004738:0.005906:0.009168:0.011665:0.003421:0.011716:0.011118:0.016044:0.003421:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738
of non-Hodgkin’s lymphomas and other :@0.559983:0.865152:0.919294:0.865152:0.919294:0.851147:0.559983:0.851147:0.011203:0.005371:0.011306:0.010434:0.011203:0.010434:0.005679:0.011682:0.011203:0.011716:0.011511:0.008586:0.003421:0.010434:0.006004:0.006636:0.011306:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.016044:0.011682:0.006636:0.011306:0.011682:0.010434:0.011716:0.011306:0.011203:0.005798:0.010434:0.011118:0.005148:0.004738
haemolymphopoietic neoplasms in people :@0.559983:0.879287:0.919289:0.879287:0.919289:0.865282:0.559983:0.865282:0.010434:0.011682:0.011118:0.016044:0.011203:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.011665:0.011203:0.003421:0.011118:0.005798:0.003421:0.011067:0.003852:0.010434:0.011118:0.011203:0.011665:0.003421:0.011682:0.006636:0.016044:0.006636:0.003866:0.003421:0.010434:0.003857:0.011665:0.011118:0.011203:0.011665:0.003421:0.011118:0.004738
with AIDS. :@0.559983:0.893421:0.645641:0.893421:0.645641:0.879416:0.559983:0.879416:0.014214:0.003421:0.005798:0.010434:0.004550:0.012657:0.003866:0.012726:0.008518:0.004738:0.004738
Lancet Oncol:@0.645453:0.893421:0.758992:0.893421:0.758992:0.879416:0.645453:0.879416:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798:0.004550:0.014864:0.010434:0.011067:0.011203:0.003421
. 2003;4(2):110-119. :@0.758992:0.893421:0.919263:0.893421:0.919263:0.879416:0.758992:0.879416:0.004738:0.004550:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.006312:0.009496:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738:0.004738
doi:10.1016/S1470-2045(03)00983-5.:@0.559983:0.907556:0.848978:0.907556:0.848978:0.893551:0.559983:0.893551:0.011716:0.011203:0.003421:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.008518:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.009476:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.004738
8. :@0.523636:0.921691:0.542588:0.921691:0.542588:0.907685:0.523636:0.907685:0.009476:0.004738:0.004738
  Grulich AE, van Leeuwen MT, Falster MO, :@0.559983:0.921691:0.897965:0.921691:0.897965:0.907685:0.559983:0.907685:0.004738:-0.004738:0.014915:0.005148:0.010399:0.003421:0.003421:0.011067:0.010434:0.004430:0.012657:0.009168:0.004738:0.004430:0.009476:0.011682:0.010434:0.004430:0.007902:0.011118:0.011118:0.010399:0.014214:0.011118:0.010434:0.004418:0.015719:0.005537:0.004738:0.004430:0.008296:0.011682:0.003421:0.006636:0.005798:0.011118:0.005148:0.004430:0.015719:0.014864:0.004738:0.004738
et :@0.897657:0.921691:0.919311:0.921691:0.919311:0.907685:0.897657:0.907685:0.011118:0.005798:0.004738
al.:@0.559983:0.935825:0.579824:0.935825:0.579824:0.921820:0.559983:0.921820:0.011682:0.003421:0.004738
 Incidence of cancers in people with HIV/:@0.579824:0.935825:0.914556:0.935825:0.914556:0.921820:0.579824:0.921820:0.003404:0.003866:0.010434:0.011067:0.003421:0.011716:0.011118:0.010434:0.011067:0.011118:0.003404:0.011203:0.005371:0.003404:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.006636:0.003404:0.003421:0.010434:0.003404:0.011665:0.011118:0.011203:0.011665:0.003421:0.011118:0.003404:0.014214:0.003421:0.005798:0.010434:0.003404:0.011682:0.003866:0.012007:0.007475